Neurogene Inc. (NGNE)
NASDAQ · Healthcare
$37.34+0.08%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $589.58M
- P/E ratio
- —
- EPS
- —
- Volume
- 158,117
- 52-week high
- —
- 52-week low
- —
- Open
- $37.32
- Day high
- $37.88
- Day low
- $36.38
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | $0 | -$90.35M | -$4.24 |
| 2024 | $925K | -$75.14M | -$4.28 |
| 2023 | $0 | -$36.32M | $2.93 |
| 2022 | — | -$55.19M | -$1.04 |
| 2021 | — | -$60.69M | -$1.10 |
About Neurogene Inc.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
- CEO
- Rachel L. McMinn
- Employees
- 131
- Country
- US
- IPO date
- Mar 7, 2014
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Neurogene Inc.'s stock price today?
- NGNE is trading at $37.34 as of Jul 20, 2026.
- What is Neurogene Inc.'s market cap?
- Neurogene Inc. (NGNE) has a market capitalization of $589.58M.
- Does Neurogene Inc. pay a dividend?
- Neurogene Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Neurogene Inc. in?
- Neurogene Inc. operates in the Healthcare sector.